Baxdrostat for Treatment-Resistant Hypertension

To the Editor: The BrigHTN trial (Feb. 2 issue)(1) showed that baxdrostat lowered blood pressure in patients with treatment-resistant hypertension in a dose-dependent manner. The use of background antihypertensive medication was similar in the baxdrostat groups and the placebo group. However, the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors in this trial was not mentioned. Because approximately 40% of the participants had diabetes, many of them were probably treated with SGLT2 inhibitors. SGLT2 inhibitors increase urinary excretion of sodium and glucose, leading to increasing urine volume and decreasing water retention.(2) SGLT2 inhibitors have been shown to lower systolic and diastolic . . .